The FDA is asking the advisory committee to vote on whether ADAGIO provides "compelling" evidence that the 1-mg dose met the protocol-specified criteria for success, whether the 2-mg group failed to meet those criteria and whether there is substantial evidence of effectiveness for Azilect as therapy to delay clinical progression of Parkinson’s disease.
This coverage is provided courtesy of "The Pink Sheet." This news organization and "The Pink Sheet" are owned by Elsevier.